Question 1

What are the risk factors for pediatric cancer, the way smoking and alcohol are known risk factors in adults?

Dr. Arun Singh Danewa · Accepted Answer

Only about 1% of pediatric tumors are familial or have an identifiable genetic cause. Most arise from spontaneous mutations that the body's own immune checkpoints fail to catch. There is no equivalent of smoking or alcohol as a modifiable risk factor in children, and no established viral cause, so there is currently no basis for a preventive vaccine.

Question 2

Can you recommend a textbook on pediatric cancers that doctors can follow?

Dr. Arun Singh Danewa · Accepted Answer

Dr. Danewa recommended Nathan and Oski's Hematology and Oncology of Infancy and Childhood as the primary reference, alongside Lanzkowsky's Manual of Pediatric Hematology and Oncology, and offered to share his own treatment protocols and presentations directly with any doctor who requests them.

Question 3

Is targeted therapy readily available, and what does it cost?

Dr. Arun Singh Danewa · Accepted Answer

For relapsed ALL, inotuzumab and blinatumomab are both available. Inotuzumab is the more affordable option since it only requires day-care admission, roughly 10,000 to 12,000 US dollars per cycle (day 1, 8 and 15), and some manufacturers offer buy-one-get-one support schemes. Blinatumomab is costlier, at 30 to 40 lakh Indian rupees, because it requires 28 days of hospitalization with continuous infusion, so it is used far less often for international patients. Anti-GD2 therapy (dinutuximab) for neuroblastoma runs around 70 to 80 lakh rupees, though the price has been coming down.

Question 4

In US dollar terms, what is a rough ballpark for what families should expect these targeted therapies to cost?

Dr. Arun Singh Danewa · Accepted Answer

Dr. Danewa put inotuzumab at roughly 10,000 to 12,000 US dollars per cycle, noted that the 70 to 80 lakh rupee cost of dinutuximab converts to about 80,000 US dollars, and priced brentuximab plus nivolumab immunotherapy for Hodgkin lymphoma in a similar range to inotuzumab, around 12,000 to 15,000 US dollars.

Question 5

Can you briefly touch on the role of stem cell transplant in pediatric care?

Dr. Arun Singh Danewa · Accepted Answer

Dr. Danewa explained that upfront bone marrow transplant has no role in most pediatric leukemia. It is reserved for cases without morphological remission (blasts above 10% at the end of induction), for hypodiploidy (fewer than 44 chromosomes), or for relapse. For benign conditions, the leading indication, especially in Africa, is sickle cell disease, where earlier transplant, ideally before age 12 and before pain crises, stroke or chest syndrome accumulate, gives a better outcome. He described three transplant types: matched sibling, matched unrelated donor via registry, and haploidentical transplant from a parent, with haploidentical success running around 70 to 80% depending on the underlying disease.

Question 6

Other than cancer, do you offer bone marrow transplant for disorders like sickle cell disease, and is there a cure?

Dr. Arun Singh Danewa · Accepted Answer

Yes. Dr. Danewa confirmed bone marrow transplant is a cure for sickle cell disease, and that outcomes are best the earlier it is done, since delay allows organ damage and comorbidities to accumulate and lowers the chance of success.

Question 7

How effective is CAR T-cell therapy?

Dr. Arun Singh Danewa · Accepted Answer

In relapsed or refractory leukemia, where prior treatment options offered only a 5 to 10% chance of success, both Western data and four to five years of follow-up on India's own indigenous CAR T-cell programs are now showing 50 to 60% success.

Question 8

For laymen, where does CAR T-cell therapy sit compared to chemotherapy, immunotherapy and targeted therapy? Is it tailored to the tumor's genetic makeup?

Dr. Arun Singh Danewa · Accepted Answer

Dr. Danewa explained that CAR T-cell therapy targets surface antigens on the cancer cell itself, such as CD19 or CD22 in ALL: a patient's own T cells are removed, engineered to recognize that antigen, and returned to attack the cancer directly. Because cancer cells can develop antigen escape by losing one target, dual CAR T-cell therapy now targets CD19 and CD22 together, and similar antigen-targeted approaches (anti-GD2) are being developed for neuroblastoma and, increasingly, for brain tumors.

Childhood Cancer: The Journey from Despair to Durable Survival

Questions Doctors Asked Dr. Arun Singh Danewa